107 related articles for article (PubMed ID: 20658363)
1. [Efficacy of tyrosine kinase inhibitor therapy combined with surgical resection in patients with metastatic gastrointestinal stromal tumor].
Zhang XH; He YL; Chen CQ; Zhan WH; Ma JP; Cai SR; Wu KM; Chen JH
Zhonghua Wei Chang Wai Ke Za Zhi; 2010 Jul; 13(7):502-5. PubMed ID: 20658363
[TBL] [Abstract][Full Text] [Related]
2. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors.
Raut CP; Posner M; Desai J; Morgan JA; George S; Zahrieh D; Fletcher CD; Demetri GD; Bertagnolli MM
J Clin Oncol; 2006 May; 24(15):2325-31. PubMed ID: 16710031
[TBL] [Abstract][Full Text] [Related]
3. Role of operative therapy in treatment of metastatic gastrointestinal stromal tumors.
Zaydfudim V; Okuno SH; Que FG; Nagorney DM; Donohue JH
J Surg Res; 2012 Oct; 177(2):248-54. PubMed ID: 22831567
[TBL] [Abstract][Full Text] [Related]
4. Managing progressive disease in patients with GIST: factors to consider besides acquired secondary tyrosine kinase inhibitor resistance.
Patel S
Cancer Treat Rev; 2012 Aug; 38(5):467-72. PubMed ID: 22035971
[TBL] [Abstract][Full Text] [Related]
5. Surgical resection of residual disease in initially inoperable imatinib-resistant/intolerant gastrointestinal stromal tumor treated with sunitinib.
Ruka W; Rutkowski P; Szawłowski A; Nowecki Z; Debiec-Rychter M; Grzesiakowska U; Dziewirski W; Siedlecki JA; Michej W
Eur J Surg Oncol; 2009 Jan; 35(1):87-91. PubMed ID: 18289826
[TBL] [Abstract][Full Text] [Related]
6. Cost effectiveness of tyrosine kinase inhibitor therapy in metastatic gastrointestinal stromal tumors.
Blanke CD; Huse DM
J Med Econ; 2010; 13(4):681-90. PubMed ID: 21067355
[TBL] [Abstract][Full Text] [Related]
7. Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after tyrosine kinase inhibitor therapy: a novel form of tumor progression.
Liegl B; Hornick JL; Antonescu CR; Corless CL; Fletcher CD
Am J Surg Pathol; 2009 Feb; 33(2):218-26. PubMed ID: 18830121
[TBL] [Abstract][Full Text] [Related]
8. Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib.
Janeway KA; Albritton KH; Van Den Abbeele AD; D'Amato GZ; Pedrazzoli P; Siena S; Picus J; Butrynski JE; Schlemmer M; Heinrich MC; Demetri GD
Pediatr Blood Cancer; 2009 Jul; 52(7):767-71. PubMed ID: 19326424
[TBL] [Abstract][Full Text] [Related]
9. A role for adjuvant RFA in managing hepatic metastases from gastrointestinal stromal tumors (GIST) after treatment with targeted systemic therapy using kinase inhibitors.
Hakimé A; Le Cesne A; Deschamps F; Farouil G; Boudabous S; Aupérin A; Domont J; Debaere T
Cardiovasc Intervent Radiol; 2014 Feb; 37(1):132-9. PubMed ID: 23589213
[TBL] [Abstract][Full Text] [Related]
10. Management of recurrent gastrointestinal stromal tumors.
Winer JH; Raut CP
J Surg Oncol; 2011 Dec; 104(8):915-20. PubMed ID: 21337345
[TBL] [Abstract][Full Text] [Related]
11. Second line therapies for the treatment of gastrointestinal stromal tumor.
Joensuu H
Curr Opin Oncol; 2007 Jul; 19(4):353-8. PubMed ID: 17545799
[TBL] [Abstract][Full Text] [Related]
12. Combined treatment strategies in gastrointestinal stromal tumors (GISTs) after imatinib and sunitinib therapy.
Pantaleo MA; Nannini M; Di Battista M; Catena F; Biasco G
Cancer Treat Rev; 2010 Feb; 36(1):63-8. PubMed ID: 19914780
[TBL] [Abstract][Full Text] [Related]
13. A decade of tyrosine kinase inhibitor therapy: Historical and current perspectives on targeted therapy for GIST.
Blay JY
Cancer Treat Rev; 2011 Aug; 37(5):373-84. PubMed ID: 21195552
[TBL] [Abstract][Full Text] [Related]
14. Outcome of metastatic GIST in the era before tyrosine kinase inhibitors.
Gold JS; van der Zwan SM; Gönen M; Maki RG; Singer S; Brennan MF; Antonescu CR; De Matteo RP
Ann Surg Oncol; 2007 Jan; 14(1):134-42. PubMed ID: 17080234
[TBL] [Abstract][Full Text] [Related]
15. Role of surgery combined with kinase inhibition in the management of gastrointestinal stromal tumor (GIST).
Hohenberger P; Eisenberg B
Ann Surg Oncol; 2010 Oct; 17(10):2585-600. PubMed ID: 20407930
[TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib -- analysis of prognostic factors (EORTC-STBSG collaborative study).
Bauer S; Rutkowski P; Hohenberger P; Miceli R; Fumagalli E; Siedlecki JA; Nguyen BP; Kerst M; Fiore M; Nyckowski P; Hoiczyk M; Cats A; Casali PG; Treckmann J; van Coevorden F; Gronchi A
Eur J Surg Oncol; 2014 Apr; 40(4):412-9. PubMed ID: 24491288
[TBL] [Abstract][Full Text] [Related]
17. Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST.
Gronchi A; Fiore M; Miselli F; Lagonigro MS; Coco P; Messina A; Pilotti S; Casali PG
Ann Surg; 2007 Mar; 245(3):341-6. PubMed ID: 17435538
[TBL] [Abstract][Full Text] [Related]
18. Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor.
Prior JO; Montemurro M; Orcurto MV; Michielin O; Luthi F; Benhattar J; Guillou L; Elsig V; Stupp R; Delaloye AB; Leyvraz S
J Clin Oncol; 2009 Jan; 27(3):439-45. PubMed ID: 19064982
[TBL] [Abstract][Full Text] [Related]
19. Controversies in the surgical management of GIST in the era of imatinib.
Raut CP; Bertagnolli MM
Oncology (Williston Park); 2009 Jan; 23(1):69, 74-6. PubMed ID: 19283924
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experience.
Rutkowski P; Gronchi A; Hohenberger P; Bonvalot S; Schöffski P; Bauer S; Fumagalli E; Nyckowski P; Nguyen BP; Kerst JM; Fiore M; Bylina E; Hoiczyk M; Cats A; Casali PG; Le Cesne A; Treckmann J; Stoeckle E; de Wilt JH; Sleijfer S; Tielen R; van der Graaf W; Verhoef C; van Coevorden F
Ann Surg Oncol; 2013 Sep; 20(9):2937-43. PubMed ID: 23760587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
